Pharmaceutical

Rhythm seeks market expansion for Imcivree following Phase III victory

Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% weight loss.

Apr 8, 2025 - 06:00
Rhythm seeks market expansion for Imcivree following Phase III victory
Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% weight loss.
Read the original article

Tags:

Previous Article

AD/PD 2025: First real-world data report for Leqembi focuses on operational chal...

Next Article

China’s NMPA authorises Santen’s glaucoma treatment application

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest

STAT+: Here are the cancer drugs Pfizer thinks could re...

Feb 29, 2024

Out with the old, in with the new: Decoding biosimilar access with VPAG 

Out with the old, in with the new: Decoding biosimilar ...

Jan 31, 2024

Opinion: Checklists to screen for patients’ social needs aren’t helping

Opinion: Checklists to screen for patients’ social need...

May 23, 2023